A Low-Modulus Phosphatidylserine-Exposing Microvesicle Alleviates Skin Inflammation via Persistent Blockade of M1 Macrophage Polarization
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(1), С. 394 - 394
Опубликована: Янв. 4, 2025
Inflammatory
skin
diseases
comprise
a
group
of
conditions
characterized
by
damage
to
function
due
overactive
immune
responses.
These
disorders
not
only
impair
the
barrier
but
also
deteriorate
quality
life
and
increase
risk
psychiatric
issues.
Here,
low-modulus
phosphatidylserine-exposing
microvesicle
(deformed
PSV,
D-PSV)
was
produced,
characterized,
evaluated
for
its
potential
therapeutic
against
diseases.
Compared
conventional
PSVs
(C-PSVs),
D-PSVs
exhibited
more
robust
longer-lasting
inhibitory
effect
on
inflammatory
response
triggered
lipopolysaccharides
interferon-γ
in
primary
bone
marrow-derived
macrophage
model.
Transcriptome
analysis
indicated
that
mainly
achieved
modulating
inflammation-related
signaling
pathways,
leading
reduction
expressions
pro-inflammatory
genes.
In
an
imiquimod-induced
psoriatic
dermatitis
mouse
model,
topical
application
effectively
mitigated
inflammation
microenvironment
reduced
lesion
severity.
improvements
were
attributed
superior
permeability
persistent
adhesion
macrophages
compared
with
C-PSVs.
summary,
this
macrophage-targeted
offers
promising
non-invasive
approach
managing
persistently
inhibiting
M1
polarization
restoring
balance.
Язык: Английский
Medication-related perceptions of children and adolescents with severe asthma and moderate-to-severe atopic dermatitis: a non-interventional exploratory study
Allergy Asthma and Clinical Immunology,
Год журнала:
2025,
Номер
21(1)
Опубликована: Апрель 7, 2025
Abstract
Background
Severe
asthma
and
moderate-to-severe
atopic
dermatitis
can
significantly
impact
the
lives
of
children
adolescents.
However,
real-world
data
on
pediatric
patients’
perceptions
their
medication
are
limited.
Methods
This
non-interventional
cross-sectional
study
at
a
university
hospital
explored
perceptions.
We
included
patients
aged
between
6
17
with
severe
and/or
dermatitis.
For
treated
dupilumab,
minimum
dupilumab
treatment
duration
16
weeks
was
required.
conducted
one
structured
interview
per
patient,
based
questionnaire
consisting
open
questions
ratings
6-point
Likert
scales
(response
scale
range:
“0:
not
all”
to
“5:
very
strongly”).
Results
The
57
participants
(severe
asthma:
n
=
31;
dermatitis:
21;
both:
5)
who
reported
“rather
moderate”
burden
(median:
2;
Q25/Q75:
0.3/2.8)
or
(3;
1.5/3.5).
They
experienced
current
medications
as
helpful”
(asthma:
4;
3/5;
3/5).
Twelve
(21%)
refusing
take
because
reluctance,
but
all
resumed
treatment.
All
receiving
therapy
(
16)
an
improvement
in
disease
within
maximum
2.5
months
after
starting
median
fear
injection
decreased
from
3
(0/5)
before
first
0.5
(0/1)
time
survey.
Conclusions
In
this
real-world,
interview-based
study,
we
found
that
perceived
highly
beneficial
for
Furthermore,
seemed
respond
well
terms
both
less
injection.
Trial
registration
DRKSID
DRKS00028092
Язык: Английский